Post Traumatic Stress Disorder Clinical Trial
Official title:
Measuring the Biochemical and Physiological Response to Controlled Stressogenic Stimuli
Verified date | August 2019 |
Source | The Chaim Sheba Medical Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Post-traumatic stress disorder (PTSD) is characterized by physiological changes, some of
which are thought to be chronic, while others are observed in response to stressogenic
stimuli. A psychiatric diagnosis of PTSD is currently based mainly on non-quantitative
elements, such as interviews and subjective impressions. Discernable patterns of
stress-related measures may constitute a physiological and biochemical phenotype
characteristic of PTSD, which may serve as a biomarker and support diagnostic decisions, as
well as personalized treatment plans.
The current study is aimed at examining the possibility of basing a psychiatric diagnosis by
measuring changes in the biochemical phenotype of participants with PTSD. Physiological and
biochemical data will be collected from participants with and without PTSD using wearable
sensors and adhesive biosensor patches. The data will be collected in two conditions: in a
neutral, quiet situation, and during and following exposure to controlled stressogenic
stimuli.
Status | Not yet recruiting |
Enrollment | 50 |
Est. completion date | June 2020 |
Est. primary completion date | February 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility |
Inclusion Criteria: - PTSD diagnosis (excluding controls) - Proper ability to give informed consent Exclusion Criteria: - Active oncological/cardiovascular condition - Dialysis patients - Active psychotic or suicidal symptoms - Severe dissociative symptoms - A traumatic brain injury (TBI) diagnosis - Pregnancy |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Nadav Goldental |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Significant differences between groups - HRV | Significant differences in Heart Rate Variability - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli | 3 hours | |
Primary | Significant differences in physiological changes between groups - temperature | Significant differences in physiological changes - body temperature- between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli | 3 hours | |
Primary | Significant differences in physiological changes between groups - SPO2 | Significant differences in physiological changes - Saturation SPO2- between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli | 3 hours | |
Primary | Significant differences in physiological changes between groups - blood pressure | Significant differences in physiological changes - continuous blood pressure- between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli | 3 hours | |
Primary | Significant differences in physiological changes between groups - pulse pressure | Significant differences in physiological changes - pulse pressure - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli | 3 hours | |
Primary | Significant differences in physiological changes between groups -respiratory rate | Significant differences in physiological changes - respiratory rate- between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli | 3 hours | |
Primary | Significant differences in physiological changes between groups -stroke volume | Significant differences in physiological changes - stroke volume- between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli | 3 hours | |
Primary | Significant differences in physiological changes between groups -cardiac output | Significant differences in physiological changes - cardiac output - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli | 3 hours | |
Primary | Significant differences in physiological changes between groups - systemic vascular resistance | Significant differences in physiological changes - systemic vascular resistance- between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli | 3 hours | |
Primary | Significant differences in cortisol levels between groups | Significant differences in biochemical changes - cortisol - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli | 3 hours | |
Primary | Significant differences in biochemical changes between groups - C-reactive protein | Significant differences in biochemical changes - C-reactive protein - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli | 3 hours | |
Primary | Significant differences in biochemical changes between groups - Interleukin 6 | Significant differences in biochemical changes - Interleukin 6 - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli | 3 hours | |
Primary | Significant differences in biochemical changes between groups - N-terminal B-type natriuretic peptide | Significant differences in biochemical changes - N-terminal B-type natriuretic peptide - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli | 3 hours | |
Primary | Significant differences in biochemical changes between groups - 8-oxo-7 | Significant differences in biochemical changes - 8-oxo-7- between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli | 3 hours | |
Primary | Significant differences in biochemical changes between groups - 8-dihydro-2'-deoxyguanosine | Significant differences in biochemical changes - 8-dihydro-2'-deoxyguanosine - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli | 3 hours | |
Primary | Significant differences in biochemical changes between groups - hexanone | Significant differences in biochemical changes - hexanone - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli | 3 hours | |
Primary | Significant differences in biochemical changes between groups - acetic acid | Significant differences in biochemical changes - acetic acid - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli | 3 hours | |
Primary | Significant differences in biochemical changes between groups - heptane | Significant differences in biochemical changes - heptane - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli | 3 hours | |
Primary | Significant differences in biochemical changes between groups - hexanal | Significant differences in biochemical changes -hexanal - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli | 3 hours | |
Primary | Significant differences in biochemical changes between groups - 3-heptanone | Significant differences in biochemical changes - 3-heptanone - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli | 3 hours | |
Primary | Significant differences in biochemical changes between groups - hexanoic acid | Significant differences in biochemical changes - hexanoic acid - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli | 3 hours | |
Primary | Significant differences in biochemical changes between groups - heptanal | Significant differences in biochemical changes -heptanal - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli | 3 hours | |
Primary | Significant differences in biochemical changes between groups - nonanal | Significant differences in biochemical changes - nonanal - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli | 3 hours | |
Primary | Significant differences in biochemical changes between groups - glucose | Significant differences in biochemical changes - glucose - between groups (participants with PTSD and controls) before and after exposure to stressogenic stimuli | 3 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05915013 -
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
|
Phase 1 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Recruiting |
NCT05934162 -
Efficacy of Internet-delivered Cognitive-behavior Therapy for PTSD
|
N/A | |
Recruiting |
NCT05934175 -
Intensive Treatment Versus Standard Weekly Prolonged Exposure for Adults With Post-Traumatic Stress Disorder
|
N/A | |
Completed |
NCT04460014 -
Simple Cognitive Task Intervention After Trauma During COVID-19 In Hospital Staff EKUT-P RCT
|
N/A | |
Completed |
NCT05877807 -
Effect of Baclofen to Prevent Post-Traumatic Stress Disorder
|
||
Active, not recruiting |
NCT05992649 -
The Effect of Aquatic Physiotherapy on Veterans Suffering From PTSD - a 40-week Pilotproject
|
N/A | |
Terminated |
NCT04404712 -
FAAH Availability in Psychiatric Disorders: A PET Study
|
Early Phase 1 | |
Not yet recruiting |
NCT05331534 -
Effect of Attentional Therapy on Post-traumatic Stress Disorder
|
N/A | |
Not yet recruiting |
NCT03649607 -
Accelerated Resolution Therapy for HIV Positive African, Caribbean and Black
|
N/A | |
Not yet recruiting |
NCT02545192 -
A Pilot Study of Low Field Magnetic Stimulation in PTSD: Three Daily Treatments
|
Phase 1 | |
Completed |
NCT02329418 -
Written Document to Assist Family During Decision of Withholding and Withdrawing Life-sustaining Therapies in the Intensive Care Unit
|
N/A | |
Active, not recruiting |
NCT00978484 -
A Head-to-head Comparison of Virtual Reality Treatment for Post Traumatic Stress Disorder
|
Phase 3 | |
Completed |
NCT00760734 -
Hyperbaric Oxygen Therapy (HBOT) in Chronic Traumatic Brain Injury (TBI)/Post Concussion Syndrome (PCS) and TBI/Post-Traumatic Stress Disorder (PTSD)
|
Phase 1 | |
Completed |
NCT03278171 -
Early Detection of Patients at Risk of Developing a Post-traumatic Stress Disorder After a Stay in Intensive Care Unit
|
||
Recruiting |
NCT05874362 -
People Bereaved by Violent Death : Negative Event Biases and Temporal Perception
|
N/A | |
Terminated |
NCT03898843 -
Assisted Animal Therapy: ReAnimal
|
N/A | |
Recruiting |
NCT04747379 -
Psychological Effect of Explicit Recall After Sedation (PEERS)
|
||
Completed |
NCT03248167 -
Cannabidiol as a Treatment for AUD Comorbid With PTSD
|
Phase 1/Phase 2 | |
Recruiting |
NCT03503981 -
Examining Change Mechanisms in Psychotherapy
|